Comparative effectiveness of sodium-glucose cotransporter-2 versus dipeptidyl peptidase-4 inhibitors on all-cause mortality in type 2 diabetes: a multinational propensity score-matched cohort study.
Diabetes patients on SGLT2 inhibitors had half the mortality rate of those on alternative drugs over five years, confirming this medication's life-extending benefits.
A multinational propensity score-matched cohort study of 323,900 T2DM patients demonstrates SGLT2 inhibitors are associated with 49% lower all-cause mortality compared to DPP-4 inhibitors over 5 years (HR 0.513). Results were consistent across all major subgroups and validated in an independent external cohort, providing the largest real-world evidence base reinforcing SGLT2i as the preferred antidiabetic agent.
What the study was
- Study design
- cohort_study
- Population
- Adults with T2DM initiating SGLT2i or DPP-4i (TriNetX multinational database 2015-2019)
- Sample size
- 323900
- Category
- Cardiometabolic Therapeutics
- Maturity
- Validated
- Journal
- Diabetes Metab
Why it surfaced
Largest real-world SGLT2i vs DPP4i mortality comparison (n=323,900 matched pairs); 49% all-cause mortality reduction confirmed across all subgroups and externally validated; direct guideline-supporting evidence reinforcing SGLT2i first-line preference in T2DM.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.